tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Akash Tewari, 64 are a BUY (71.91%), 22 are a HOLD (24.72%), 3 are a SELL (3.37%).
Analyst Akash Tewari, currently employed at WOLFE, carries an average stock price target met ratio of 56.19% that have a potential upside of 27.89% achieved within 204 days. Previously, Akash Tewari worked at JEFFERIES.
Akash Tewari’s has documented 170 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 15-Nov-2024.
Analyst best performing recommendations are on ARVN (ARVINAS).
The best stock recommendation documented was for ARVN (ARVINAS) at 6/21/2022. The price target of $42 was fulfilled within 2 days with a profit of $3.11 (8%) receiving and performance score of 39.98.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$40
$10.29 (34.63%)
$35
1 months 8 days ago
(13-Nov-2024)
0/6 (0%)
$10.84 (37.17%)
Hold
$36
$6.29 (21.17%)
$33
1 months 16 days ago
(05-Nov-2024)
19/25 (76%)
$8.26 (29.78%)
143
Hold
$26
$-3.71 (-12.49%)
$32
1 months 26 days ago
(25-Oct-2024)
6/7 (85.71%)
$-0.09 (-0.34%)
64
Buy
$30
$0.29 (0.98%)
$37
1 months 26 days ago
(25-Oct-2024)
8/16 (50%)
$3.91 (14.99%)
342
Buy
$37
$7.29 (24.54%)
$39
1 months 26 days ago
(25-Oct-2024)
3/8 (37.5%)
$10.91 (41.82%)
101
Which stock is Akash Tewari is most bullish on?
Which stock is Akash Tewari is most reserved on?
What Year was the first public recommendation made by Akash Tewari?
